Advanced searches left 3/3

Dolutegravir - Crossref

Summarized by Plex Scholar
Last Updated: 22 June 2022

* If you want to update the article please login/register

“It’s only fatness, it doesn’t kill”: a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda

In women living in Uganda with HIV, our research examined results of weight gain from a DTG-based diet on body image and adoption of antiretroviral therapy. Methods Between April and June 2021, we conducted semi-structured interviews involving 25 WLHIV and 19 healthcare professionals randomly selected from HIV clinics in Kampala. Results Our findings reveal that WLHIV in Uganda generally disliked thin body shape and aspired to gain moderate to high body weight in order to lift their body image, social standing, and mask their sero-positive status. Both WLHIV and healthcare professionals largely associated weight gain with DTG use, although it was not widely distributed or to change medication adherence, and it was unlikely to be reported or altered medication adherence. Conclusions The study found that large body-size does not appear to be helpful in fostering psychosocial stability in WLHIV in Uganda.

Source link: https://doi.org/10.1186/s12905-022-01814-x


Development and Validation of Stability Indicating Related Substances Method for Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate (DLT) Tablets using High Performance Liquid Chromatography

The RP-LC method was applied to a 250 x 4. 6 mm, 5 m, C18 column, with a gradient mode in which phosphate buffer and phosphoric acid were mixed in methanol and water as the mobile phase.

Source link: https://doi.org/10.52711/0974-360x.2022.00356


Case Report: Successful treatment with Dolutegravir containing antiretroviral therapy for acute on chronic liver failure by HBV in patients with HIV infection

Abstract Background: Since the overwhelming majority of antiretroviral drugs have hepatotoxicity, there is no simple antiretroviral therapy for HIV/HBV co-infected patients with acute-on-chronic liver disease in patients with acute-on-chronic liver failure. Results: Two cases of HIV/HBV coinfection with ACLF were successfully treated with DTG HAART, including DTG, and were not liver damage, immune reconstitution inflammatory syndrome, or other complications.

Source link: https://doi.org/10.21203/rs.3.rs-1755191/v1


RP-HPLC method for swift analysis of Lamivudine and Dolutegravir in formulation, stability studies

The new RP-HPLC method was developed for simultaneous measurement of lamivudine and dolutegravir in pharmaceutical dosage forms and used to stability studies of drugs. On the Std discovery C18 column, the title analytes were eluted rapidly with phosphate buffer and acetonitrile. With good resolution, Lamivudine and Dolutegravir were eluted at 2. 37 min and 2. 97 min respectively. According to 18. 75 - 112. 5 mL and 3. 125 - 18. 75 - 18. 75 - 18. 75 g/mL, respectively. The reproducibility of the method is shown by the % RSD values in precision studies.

Source link: https://doi.org/10.52711/2231-5675.2022.00019


Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation

Abstract A series of monomeric and dimeric dolutegravir prodrug nanoformulations were developed for the introduction of ultra-long-acting integrase strand transfer inhibitors by screening a repository of monomeric and dimeric dolutegravir prodrug nanoformulations. Following single parenteral injection, we show that the physiological and pharmacokinetic formulation characteristics of tissue macrophage depot stores at the muscle injection site and adjacent lymphoid tissues promote drug release from tissue macrophage depot stores. Both resource poor and wealthy settings can be impacted by the NM2DTG's drug adherence, tolerability, and access to a commonly used integrase inhibitor in both resource limited and wealthy settings to reduce HIV-1 transmission and achieve optimal treatment outcomes.

Source link: https://doi.org/10.1038/s41467-022-30902-7


A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy

In a clinical trial in Uganda and South Africa, we compared HRQoL of treatment-nau00efve pregnant women randomized to dolutegravir- or efavirenz-based ART. PHS were higher in the dolutegravir-based arm, while MHS were higher for women in the efavirenz-based armat 24 and 48 weeks. A rise in MHS scores was associated with higher PHS scores when owning a bank account, using the internet, and longer treatment duration were all associated with an increase in MHS scores. In late pregnancy, we found no significant differences in HRQoL outcomes among HIV-positive women starting on dolutegravir relative to efavirenz. In the first year, HRQoL's increase in HRQoL increased in HRQoL in the first year after the administration of ART in HIV-positive women who are presenting late in pregnancy.

Source link: https://doi.org/10.1186/s12981-022-00446-3


Inhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes

For people living with HIV, treatment with integrase-strand-transfer-inhibitors can lead to adipose tissue gain. The emergence of beige adipocytes in white AT may play a significant role in limiting excess lipid storage and associated adipocyte dysfunction while also increasing energy expenditure by boosting energy expenditure. As shown by lower expression of beige markers and lower cell respiration, Dolutegravir and bictegravir reduced beige differentiation in ASCs. Our findings show that adipocyte hypertrophy induced by INSTIs is triggered by hypoxia in fat fibrosis, beiging inhibition, and, therefore, more hypertrophy and related insulin resistance.

Source link: https://doi.org/10.3390/cells11111841


Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency Virus

Background Paper Dolutegravir is a component of common antiretroviral therapy regimens. After ART participation in the ADVANCE trial in South Africa, we characterized the pharmacogenetics of dolutegravir exposure. We developed a population pharmacokinetic model for dolutegravir using nonlinear mixed-effects modelling. Linear regression models investigated relationships with unexplained variability in the dolutegravir area under the concentration-time curve. Earlier associated with dolutegravir pharmacokinetics, the lowest P value with AUCVAR was UGT1A1 rs887829, which was also related to log10 bilirubin.

Source link: https://doi.org/10.1093/infdis/jiac174


Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression

Abstract Objectives In clinical trials or real-life cohorts, no evidence of integration has been established with co-formulated dolutegravir/lamivudine. To the best of our knowledge, the first case of the key integrase mutation R263K in a population treated with this regimen started as a switch strategy with undetectable plasma HIV-1 viraemia was reported. Despite good treatment adherence, a patient with long-term suppressed HIV-1 viraemia with no known risk factors for virologic dysfunction and never exposed an integrase inhibitor died with 322 CD4 cells/mm3 without experiencing any acute infection causes. The emergence of R263K and S230N mutations in the integrase region was confirmed by genetic deep sequencing of plasma HIV-1. Conclusions This case illustrates how integrationase resistance can develop in patients treated with coformulated dolutegravir/lamivudine, as well as raising concerns of the need to carefully investigate and monitor drug interactions, even though the target is considered low in patients treated with dolutegravir/lamivudine.

Source link: https://doi.org/10.1093/jac/dkac082

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions